Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC (RETRO-ROC)

Grupo Español de Investigación en Cáncer de Ovario

Status: Completed

Conditions: Ovarian Epithelial Cancer Recurrent

Treatments: Drug: Trabectedin and Pegylated Liposomal Doxorubicin

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02394015

GEICO 1402R

GEI-TRAB-2014-01 (Other Identifier)

Details and patient eligibility

About

Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC.

Enrollment: 90 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have received at least one dose of trabectedin - doxorubicin pegylated for recurrent ovarian cancer according to SMPC, between October 28, 2009 and October 31, 2014 and which have not been included in clinical trials where the IMP was trabectedin.

Exclusion criteria

• Patients with records unavailable (lost, empty or not recoverable).

Trial design

90 participants in 1 patient group

Trabectedin+ PLD

Description:

Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC.

Treatment:

Drug: Trabectedin and Pegylated Liposomal Doxorubicin